600sek
0,0 %
Date:2026-03-27Time:17:29:00Latest report:Q4-2025List:SpotlightTicker:ABERA
Market Cap:123 msekEnterprise Value:100 msekNet Sales:- msekEarnings:-10,5 msekEmployees:0ISIN:SE0015245097

Ratios

10-year key figure history for Abera Bioscience turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Abera Bioscience with index and moving average MA50 and MA200.

Stockprice:6,00
MA50:6,18
MA200:6,85
Price/MA200:-12,4 %
RSI (14):48,8
Price/MA50:-3,0 %

Description

Abera Bioscience is a Swedish biotechnology company that develops nasal vaccines based on a proprietary OMV-based platform technology. The company's focus is on nasal vaccines that provide immune responses in both mucosal and systemic areas. Abera develops vaccines against several respiratory infectious diseases, including pneumococci, influenza and pandemic preparedness, with projects in preclinical and planned clinical phases. The company was founded in 2012 and is headquartered in Uppsala.

Biotechnology